ElevateBio

We hosted Abata Therapeutics for a fireside chat and Q&A with their CEO, Samantha Singer, and COO, John Trzupek. ElevateBio Basecamp has been a long-time partner with Abata, collaborating to accelerate the development of their cell therapy program for multiple sclerosis (MS). The learnings from our partnership and the ABA-101 manufacturing process also serve as a template to benefit future development programs, including their investigational program for Type 1 diabetes. #Innovation #Partnership #TransformativeTherapies

"ElevateBio applies ...[the] foundry business model to genetic medicines, positioning ourselves as a one-stop shop and indispensable partner for cell and gene therapy companies, dedicated to propelling the entire field of genetic medicine forward," writes David Hallal, our Chairman and CEO, in his thought piece on how ElevateBio’s foundry model is changing the future of genetic medicines. Read more here: https://lnkd.in/eQZcaZFZ. #ThoughtLeadership #ElevateBio

We’re committed to developing life-changing therapies. Life Edit Therapeutics next-generation gene editing platform offers one of the world’s largest and most diverse libraries of RNA-guided nucleases (RGNs), base editors, and reverse transcriptase editors, providing our partners with a full spectrum of editing modalities and unlimited access to the genome– making any edit, anywhere, possible. #GeneEditing #CellAndGeneTherapy

What makes 𝘦𝘹 𝘷𝘪𝘷𝘰 therapies unique? They are “living medicines.” Immune cells and genetic material are engineered outside of the body, then reintroduced into the patient, targeting the source of disease due to its modified design. Our proprietary gene editing technologies and engineering expertise are optimizing therapies for patients in need. Learn more: https://lnkd.in/eu_erzny. #CellAndGeneTherapy #ElevateBio

We’re making significant progress towards the opening of our new 125,000-square-foot biomanufacturing facility in Pittsburgh, located in Hazelwood Green. Discover the positive impact that our new BaseCamp location will bring to Pittsburgh– a city ready to take part in leading life science! Read the full Elevated Insights here: https://lnkd.in/dAvigdAQ. #ElevatedInsights #HazelwoodGreen #BaseCamp

ElevateBio's Constantino R. and Jeffrey Cram joined the ARM Institute's Manufacturing Day on Oct 2. Welcoming high school students from Pittsburgh area schools, the event encouraged exploration of careers in manufacturing, with a focus on advanced technologies such as robotics, additive manufacturing, and artificial intelligence (AI). It was great to showcase the progress of our 125,000 sq. ft. BaseCamp biomanufacturing facility at Hazelwood Green, developed with the University of Pittsburgh, and set to open in 2027.

ElevateBio’s Michael Paglia, Chief Technology Officer, and Life Edit Therapeutics's Clare Murray, SVP, Corporate Development & Operations, participated at this year’s Cell & Gene Meeting on the Mesa. We’re proud to share our expertise and take part in shaping the future of medicine alongside industry leaders and peers. #MeetingOnTheMesa #ElevateBio

Our CEO David Hallal gave a keynote address at the Pittsburgh Life Sciences Alliance (PLSA) meeting yesterday, attended by leaders in life science, as well as select state and local officials. Offering an industry perspective, David represented ElevateBio in front of the PLSA, whose aim is to make greater Pittsburgh a global life sciences leader and economic engine at the intersection of the region’s unique clinical, research, manufacturing, and technology strengths.

We'll be presenting at Outsourced Pharma! Join Katie Jorgensen, VP, Site Head, BaseCamp, for the webinar "How to Navigate the Successful Transition from Clinical to Commercial Manufacturing in Cell Therapy" in the afternoon session on Oct 24. Register here: https://lnkd.in/d_C99vYr.  

Today we announced the successful 𝘪𝘯 𝘷𝘪𝘷𝘰 delivery of Life Edit Therapeutics' gene editing systems with our proprietary LNP platform in murine studies. Data on the studies and LNP platform will be presented at the 6th Annual Formulation & Delivery US Congress in San Diego later today. "As part of ElevateBio’s broad collection of cutting-edge technologies spanning cell, RNA, and gene editing, this platform reinforces our mission to offer comprehensive solutions to innovators across the industry that are developing genetic medicines" - Tedd Elich, Chief Scientific Officer, Life Edit Read the full press release here: https://lnkd.in/eSzNg7We